SAB Biotherapeutics
SABS
SABS
42 hedge funds and large institutions have $24.5M invested in SAB Biotherapeutics in 2023 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
3.13% more ownership
Funds ownership: 0.73% → 3.86% (+3.1%)
Holders
42
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$6.31M | |
| 2 | +$6.31M | |
| 3 | +$3.16M | |
| 4 |
SC
Sessa Capital
New York
|
+$3.15M |
| 5 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$1.63M |
Top Sellers
| 1 | -$46K | |
| 2 | -$17.4K | |
| 3 | -$14.5K | |
| 4 |
SFC
Strategic Financial Concepts
San Antonio,
Texas
|
-$9.47K |
| 5 |
ECM
Elgethun Capital Management
Sioux Falls,
South Dakota
|
-$5.35K |